Loading clinical trials...
Loading clinical trials...
A Phase 1B Dose Escalation, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-hodgkin's Lymphoma
Conditions
Interventions
CC-95775
Locations
5
France
Institut Curie
Paris, France
Hopital Saint Louis
Paris, France
Centre Eugene Marquis
Rennes, France
Hospital de Madrid Norte- Sanchinarro
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Start Date
October 24, 2019
Primary Completion Date
October 25, 2021
Completion Date
October 25, 2021
Last Updated
February 1, 2022
NCT06510361
NCT05442515
NCT07162181
NCT06528301
NCT05824585
NCT04460235
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions